KR20140035320A - 날트렉손 요법에서 약물 생체이용률의 증가 - Google Patents

날트렉손 요법에서 약물 생체이용률의 증가 Download PDF

Info

Publication number
KR20140035320A
KR20140035320A KR1020137017317A KR20137017317A KR20140035320A KR 20140035320 A KR20140035320 A KR 20140035320A KR 1020137017317 A KR1020137017317 A KR 1020137017317A KR 20137017317 A KR20137017317 A KR 20137017317A KR 20140035320 A KR20140035320 A KR 20140035320A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
naltrexone
bupropion
food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137017317A
Other languages
English (en)
Korean (ko)
Inventor
숀 플래나간
에두아르도 듀나예비치
Original Assignee
오렉시젠 세러퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140035320(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오렉시젠 세러퓨틱스 인크. filed Critical 오렉시젠 세러퓨틱스 인크.
Publication of KR20140035320A publication Critical patent/KR20140035320A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acoustics & Sound (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
KR1020137017317A 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가 Ceased KR20140035320A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
US61/419,395 2010-12-03
PCT/US2011/063177 WO2012075459A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187016354A Division KR101984500B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가

Publications (1)

Publication Number Publication Date
KR20140035320A true KR20140035320A (ko) 2014-03-21

Family

ID=46172304

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020207011510A Active KR102258043B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020137017317A Ceased KR20140035320A (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020197014576A Active KR102105857B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020217015625A Active KR102391511B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020187016354A Active KR101984500B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207011510A Active KR102258043B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197014576A Active KR102105857B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020217015625A Active KR102391511B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가
KR1020187016354A Active KR101984500B1 (ko) 2010-12-03 2011-12-02 날트렉손 요법에서 약물 생체이용률의 증가

Country Status (27)

Country Link
US (1) US20130245056A1 (OSRAM)
EP (4) EP3222280B1 (OSRAM)
JP (5) JP6008866B2 (OSRAM)
KR (5) KR102258043B1 (OSRAM)
CN (1) CN103313711A (OSRAM)
AR (2) AR093182A1 (OSRAM)
AU (2) AU2011336304B2 (OSRAM)
BR (1) BR112013013390A2 (OSRAM)
CA (2) CA3239386A1 (OSRAM)
CL (1) CL2013001564A1 (OSRAM)
CY (2) CY1118968T1 (OSRAM)
DK (3) DK3884947T3 (OSRAM)
ES (2) ES2625527T3 (OSRAM)
FI (2) FI4349369T3 (OSRAM)
HR (3) HRP20240115T1 (OSRAM)
HU (3) HUE034393T2 (OSRAM)
IL (3) IL226504B (OSRAM)
LT (3) LT2646031T (OSRAM)
MX (2) MX356801B (OSRAM)
PL (3) PL3222280T3 (OSRAM)
PT (3) PT3222280T (OSRAM)
RS (3) RS65198B1 (OSRAM)
RU (1) RU2640561C2 (OSRAM)
SI (3) SI3884947T1 (OSRAM)
SM (3) SMT202100227T1 (OSRAM)
TW (1) TWI618536B (OSRAM)
WO (1) WO2012075459A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
KR101841442B1 (ko) 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
JP6008866B2 (ja) * 2010-12-03 2016-10-19 オレキシジェン・セラピューティクス・インコーポレーテッド ナルトレキソン療法における薬物バイオアベイラビリティの増加
IL300868A (en) 2012-06-06 2023-04-01 Orexigen Therapeutics Inc Methods for treating overweight and obesity
EP3253379A4 (en) * 2015-02-07 2018-10-10 Intas Pharmaceuticals Limited Pharmaceutical composition for the treatment of obesity
KR20200072445A (ko) * 2017-03-28 2020-06-22 엘디엔 파마 리미티드 암의 치료를 위한 세포 사멸의 bcl2-관련 효능제의 발현을 증가시키는 제제
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
PT2316456T (pt) * 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
AU2006275914A1 (en) 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
AR058239A1 (es) 2005-11-28 2008-01-23 Orexigen Therapeutics Inc Metodos para tratar trastornos de ansiedad
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
PT2484346T (pt) * 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
KR101264789B1 (ko) * 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
CA2693992C (en) * 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20080110792A1 (en) * 2006-11-09 2008-05-15 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
KR101971218B1 (ko) * 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
ES2906582T3 (es) * 2007-04-11 2022-04-19 Biomarin Pharm Inc Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
JP6008866B2 (ja) * 2010-12-03 2016-10-19 オレキシジェン・セラピューティクス・インコーポレーテッド ナルトレキソン療法における薬物バイオアベイラビリティの増加

Also Published As

Publication number Publication date
SMT202100227T1 (it) 2021-07-12
CN103313711A (zh) 2013-09-18
IL279626A (en) 2021-03-01
RS62149B1 (sr) 2021-08-31
JP6008866B2 (ja) 2016-10-19
RU2017144631A (ru) 2019-02-18
KR20200044158A (ko) 2020-04-28
SI3222280T1 (sl) 2021-11-30
HUE053831T2 (hu) 2021-07-28
RU2017144631A3 (OSRAM) 2021-04-13
IL270841A (en) 2020-01-30
FI4349369T3 (fi) 2025-12-17
AR124500A2 (es) 2023-04-05
AR093182A1 (es) 2015-05-27
RU2013127423A (ru) 2015-01-10
PL3884947T3 (pl) 2024-05-06
JP6456890B2 (ja) 2019-01-23
JP2013544290A (ja) 2013-12-12
CL2013001564A1 (es) 2014-05-02
EP4349369A2 (en) 2024-04-10
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
LT3884947T (lt) 2024-03-12
PT3222280T (pt) 2021-04-22
EP4349369A3 (en) 2024-05-15
EP2646031A1 (en) 2013-10-09
MX384662B (es) 2025-03-14
AU2011336304A1 (en) 2013-07-11
EP4349369B1 (en) 2025-09-17
SMT201700232T1 (it) 2017-07-18
KR102105857B1 (ko) 2020-05-04
IL226504B (en) 2021-01-31
RS65198B1 (sr) 2024-03-29
TWI618536B (zh) 2018-03-21
HRP20210618T1 (hr) 2021-09-17
AU2017204309A1 (en) 2017-07-13
FI3884947T3 (fi) 2024-01-30
KR20180069089A (ko) 2018-06-22
KR20210063473A (ko) 2021-06-01
PT2646031T (pt) 2017-05-25
DK2646031T3 (en) 2017-05-22
CA3239386A1 (en) 2012-06-07
LT2646031T (lt) 2017-06-26
ES2625527T9 (es) 2018-09-25
US20130245056A1 (en) 2013-09-19
KR101984500B1 (ko) 2019-05-31
JP2022060331A (ja) 2022-04-14
CA2819262C (en) 2024-05-28
HRP20170734T1 (hr) 2017-08-11
EP3222280A1 (en) 2017-09-27
SI3884947T1 (sl) 2024-06-28
MX2013006071A (es) 2013-10-01
JP2024071605A (ja) 2024-05-24
EP2646031B9 (en) 2018-01-10
EP3884947B1 (en) 2023-11-15
JP2019056004A (ja) 2019-04-11
HUE034393T2 (en) 2018-02-28
DK3222280T3 (da) 2021-04-19
HUE065852T2 (hu) 2024-06-28
EP3222280B1 (en) 2021-01-20
HRP20240115T1 (hr) 2024-06-07
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
CY1118968T1 (el) 2018-01-10
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
PL3222280T3 (pl) 2021-11-29
ES2866879T3 (es) 2021-10-20
JP7025319B2 (ja) 2022-02-24
ES2625527T3 (es) 2017-07-19
AU2011336304B2 (en) 2017-03-30
CY1124331T1 (el) 2022-07-22
RU2640561C2 (ru) 2018-01-09
SMT202400038T1 (it) 2024-03-13
EP3884947A1 (en) 2021-09-29
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
EP2646031A4 (en) 2014-04-23
MX356801B (es) 2018-06-13
PT3884947T (pt) 2024-02-16
JP2016210809A (ja) 2016-12-15
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
LT3222280T (lt) 2021-05-10
KR20190058702A (ko) 2019-05-29
TW201304780A (zh) 2013-02-01

Similar Documents

Publication Publication Date Title
KR102258043B1 (ko) 날트렉손 요법에서 약물 생체이용률의 증가
US20220233520A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
RU2781141C2 (ru) Повышение биодоступности лекарственных средств при терапии налтрексоном
HK1188136A (en) Increasing drug bioavailability in naltrexone therapy
HK1188136B (en) Increasing drug bioavailability in naltrexone therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130702

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161117

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170906

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20180315

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170906

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180608